Search Results

CraniUS™, an R&D company focused on groundbreaking diagnostics and treatments for patients with chronic brain disease, has been awarded a competitive $1 million grant from the State of Maryland as part of Governor Wes Moore’s Build Our Future Innovation Infrastructure Pilot Program.

The Maryland Stem Cell Research Commission is pleased to announce the next round of awards granting a total of more than $15.4 million.

Emergent BioSolutions Inc. announced that it has entered into a definitive agreement to sell its drug product facility in Baltimore-Camden to an affiliate of Bora Pharmaceuticals Co., Ltd., a leading international pharmaceutical services company, for a total value of approximately $30 million.

The Maryland Stem Cell Research Commission announces the release of Requests for Applications for the Maryland Stem Cell Research Fund’s first funding cycle of fiscal year 2025.

BioGenCell, a pioneer in personalized cell therapy solutions, is excited to announce the launch of its fifth Phase II clinical trial site in the United States at the University of Maryland.

Precision for Medicine, a global leader in biomarker-driven clinical research and development supporting life sciences companies, announced the completion of a major expansion to its laboratory campus in Frederick, Maryland.

University of Maryland School of Medicine Dean Mark T. Gladwin, MD, and University of Maryland Medical Center President and CEO Bert W. O’Malley, MD, announced that Taofeek K. Owonikoko, MD, PhD, a distinguished physician-scientist with a global reputation in thoracic oncology, has been appointed Executive Director of the University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center.

University of Maryland School of Medicine Dean Mark T. Gladwin, MD, has announced plans to launch a new neuroscience institute that will accelerate translational research of the brain by facilitating interaction between basic and clinical scientists and enhancing collaborative research across the UMSOM and University of Maryland, Baltimore campus.

Seraxis, Inc., a regenerative medicine company developing pancreatic islet replacement therapies to transform the lives of patients with Type 1 and insulin-requiring Type 2 diabetes, has been notified that the company is the awardee of a $400,000 Commercialization Program grant from the Maryland Stem Cell Research Fund that aims to foster Maryland research to enhance and propel stem cell treatments.